In a study from the University of Arizona, scientists found the drug lasmiditan, which is used to treat migraines, shows promise as a possible treatment for acute kidney injury.
Researchers of this study are working to develop a drug to treat acute kidney injury.
The disease, which is characterized by rapid kidney failure, occurs in approximately 8% to 16% of hospitalized people and affects more than 13 million people worldwide.
The condition can be caused by a variety of factors, including some medications and sepsis.
Acute kidney injury can cause physiological problems, damage to small blood vessels in the kidney and loss of renal tubular function. Currently, there is no treatment for acute kidney injury.
In the study, the team treated a mouse model of acute kidney injury with lasmiditan and found it stimulated recovery of kidney function, improved vascular health, reduced fibrosis and reduced kidney damage.
The mice were first assigned to four groups and dosed for five consecutive days, starting at 24 hours after kidney injury.
Lasmiditan is already approved by the U.S. Food and Drug Administration for the treatment of migraines.
The team says this is a classic example of drug repurposing. More research is needed, but they believe these early results show promising signs of treatment for acute kidney injury.
If you care about kidney health, please read studies about habits that could harm your kidney health, and common painkillers may harm your heart, kidneys, and sleep.
For more information about kidney health, please see recent studies about diabetes drugs that could reduce chronic kidney disease, and results showing some common vegetables may reduce diabetes-related kidney damage.
The study was conducted by Rick Schnellmann et al and published in the American Journal of Physiology–Renal Physiology.
Copyright © 2023 Knowridge Science Report. All rights reserved.
